Boys Arnold & Co. Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,281 shares of the biopharmaceutical company’s stock after selling 10,186 shares during the period. Boys Arnold & Co. Inc.’s holdings in Pfizer were worth $4,212,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Evolution Wealth Advisors LLC acquired a new position in Pfizer during the 2nd quarter worth $34,000. IMA Wealth Inc. raised its position in shares of Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 477 shares in the last quarter. Financial Gravity Wealth Inc. raised its position in shares of Pfizer by 33.2% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 257 shares in the last quarter. Vestor Capital LLC raised its position in shares of Pfizer by 60.1% during the 2nd quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 581 shares in the last quarter. Finally, HMS Capital Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth about $71,000. 71.66% of the stock is owned by institutional investors.
PFE has been the topic of a number of recent analyst reports. UBS Group restated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group reiterated a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a report on Wednesday, August 28th. Finally, Bank of America initiated coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price on the stock. Eleven analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $44.47.
Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period last year, the firm posted $0.77 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.82 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.96%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
In other news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Scott Gottlieb bought 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.